Matches in DBpedia 2016-04 for { ?s ?p "Neboglamine (INN) (formerly nebostinel; developmental code names CR-2249, XY-2401) is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Neboglamine abstract "Neboglamine (INN) (formerly nebostinel; developmental code names CR-2249, XY-2401) is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.".
- Q20707894 abstract "Neboglamine (INN) (formerly nebostinel; developmental code names CR-2249, XY-2401) is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.".
- Neboglamine comment "Neboglamine (INN) (formerly nebostinel; developmental code names CR-2249, XY-2401) is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.".
- Q20707894 comment "Neboglamine (INN) (formerly nebostinel; developmental code names CR-2249, XY-2401) is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.".